Sino Lion Ventures Reports Dilutive Decrease in Indaptus Therapeutics Stake to 29.19%

This Amendment No. 2 to Schedule 13D was filed on June 26, 2026, by Sino Lion Ventures Limited and its controlling person, Chenhao Xu, regarding their holdings in Indaptus Therapeutics, Inc. (INDP). The Reporting Persons currently hold 38,895,000 shares of Common Stock, representing a 29.19% ownership stake based on 133,242,324 shares outstanding as of June 24, 2026. The filing reports a decrease of more than 1% in the Reporting Persons' beneficial ownership percentage. Crucially, this decrease resulted solely from dilution due to an increase in the Issuer's total outstanding shares following a private placement closed on June 17, 2026. The Reporting Persons did not actually sell or dispose of any shares; their absolute share count remains unchanged from previous filings. The shares were originally acquired through the conversion of Series AA and Series AAA Preferred Stock purchased in March 2026. The Reporting Persons continue to share voting and dispositive power over the reported 38,895,000 shares.